HAE

Haemonetics Corporation 10-Q Summary

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for Haemonetics Corporation for the three and nine months ended January 2, 1999. The company manufactures blood processing equipment and single-use disposables. The fiscal year 1999 includes 53 weeks, with an additional week added to the first quarter ended July 4, 1998.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net revenues decreased 3.6% for the quarter and 6.6% for the nine-month period compared to the prior year. At constant currency, the decline was 1.7% (quarter) and 2.1% (nine months). The decrease was driven by a significant drop in equipment sales (down ~30% quarterly, ~50% nine-month) due to a strategic shift toward placing equipment rather than selling it, and the absence of one-time plasma equipment shipments to China and a U.S. customer in 1997.
• Profitability: Operating income improved significantly to $7.2 million for the quarter from a loss of $14.3 million in the prior year, primarily due to the absence of a $24.5 million non-recurring restructuring charge in 1997. Gross margin decreased 4.2% to 46.0% for the quarter, largely due to currency effects and production slowdowns.
• Cash Flow: Net cash provided by operating activities from continuing operations increased to $29.2 million for the nine months ended Jan 2, 1999, compared to $5.3 million in the prior year. This was driven by higher net income (excluding the prior year's restructuring charge), reduced inventory investment, and a tax refund.
• Discontinued Operations: The Blood Bank Management Services (BBMS) business continues to be wound down. Operating losses for BBMS were $2.0 million for the quarter and $7.2 million for the nine months. Five BBMS operations were sold during the nine-month period.

Guidance, Outlook, and Risks

• Outlook: Management expects the annualized tax rate for fiscal 1999 to be approximately 35%. The company anticipates improved gross margins in the U.S. surgical business following the termination of its distributor relationship with Bentley Laboratories (Baxter Healthcare) effective January 1, 1999.
• Year 2000 Compliance: The company estimates total costs for Y2K compliance between $3 million and $4 million. Approximately 98% of system-related exposures have been inventoried. Management believes it is on track to complete remediation of critical systems by June 30, 1999. Risks include potential interruptions from third-party suppliers or untested embedded logic in production equipment.
• Foreign Exchange: The company holds forward exchange contracts totaling $165.5 million to hedge firm sales commitments. Gross unrealized losses on these hedges were $7.4 million as of January 2, 1999.
• Liquidity: The company believes its cash sources are adequate to meet projected needs. Net debt decreased by $26.7 million to $21.9 million during the nine-month period.

Investor Verification Checklist

• Equipment Sales Strategy: Verify the long-term impact of the shift from selling equipment to placing it on future revenue recognition and cash flow.
• Y2K Costs and Risks: Confirm the final cost of Y2K remediation and monitor for any operational disruptions from suppliers or internal systems.
• Discontinued Operations: Track the final disposition of remaining BBMS assets and liabilities to ensure no unexpected losses arise.
• Foreign Currency Exposure: Monitor the realization of the $7.4 million unrealized loss on forward contracts and its impact on future earnings.
• Red Cross Dispute: Verify the resolution status of the dispute with the American Red Cross, which resulted in a $2.6 million provision for receivables.